41.79
0.86 (2.10%)
| Previous Close | 40.93 |
| Open | 41.12 |
| Volume | 194,495 |
| Avg. Volume (3M) | 1,161,639 |
| Market Cap | 2,981,953,280 |
| Price / Book | 4.78 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Diluted EPS (TTM) | -3.00 |
| Total Debt/Equity (MRQ) | 10.18% |
| Current Ratio (MRQ) | 27.68 |
| Operating Cash Flow (TTM) | -155.26 M |
| Levered Free Cash Flow (TTM) | -97.14 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -39.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Vera Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 2.50 |
|
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.97% |
| % Held by Institutions | 112.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Integral Health Asset Management, Llc | 31 Dec 2025 | 1,800,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (HC Wainwright & Co., 163.22%) | Buy |
| Median | 99.00 (136.90%) | |
| Low | 88.00 (Wolfe Research, 110.58%) | Buy |
| Average | 99.00 (136.90%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 41.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 11 Mar 2026 | 88.00 (110.58%) | Buy | 42.04 |
| HC Wainwright & Co. | 02 Mar 2026 | 110.00 (163.22%) | Buy | 40.42 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 28 Jan 2026 | Announcement | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |